Europe Alzheimer’s Disease Drugs Market Analysis

Europe Alzheimer’s Disease Drugs Market Executive Summary

Europe's Alzheimer’s Disease Drugs market was valued at $2.93 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.16% from 2022 to 2030 and will reach $5.09 Bn in 2030. Alzheimer's disease is a type of dementia that causes problems with memory, thinking, and behavior. The symptoms gradually become severe enough to interfere with daily activities. Alzheimer's disease is the most prevalent form of dementia, which is defined as memory loss and other cognitive deficits that are severe enough to interfere with everyday life. Alzheimer's disease is responsible for 60-80% of dementia cases.

According to Alzheimer’s Europe, the number of persons living with dementia in the European Union (EU27) is projected to be 7 Mn with 9.7 Mn living in European nations represented by AE members. When compared to previous projections, this is a significant decrease from 8.7 Mn for the EU27 and 10.4 Mn for the entire European region. Due to the aging of European populations, the number of persons with dementia in Europe is anticipated to climb to 14 Mn by 2040. In recent years, the European Union, including the European Commission, the Council of the European Union, and the European Parliament, has taken several initiatives in support of dementia. These acts range from political pronouncements and conferences that have raised the visibility of dementia at the European level to financed programs and tools that have supported dementia policy, practice, and research.

Market Dynamics

Market Growth Drivers

Europe has one of the world's largest aging populations, which is another key factor driving growth in the Alzheimer's disease drugs market. As people age, they are at a higher risk of developing the disease, and as the population continues to age, the demand for drugs to treat Alzheimer's disease is likely to continue to increase. According to Eurostat data, more than one-fifth of the EU population was 65 or older in 2020, representing a 3% rise from 2010. Life expectancy in Europe is also rising, rising from an average of 77.7 years for those born in 2002 to 81.3 years for those born in 2019. There have been significant advancements in research and development of new drugs for Alzheimer's disease. This has led to the development of new drugs that are more effective and have fewer side effects than older drugs, which has increased the demand for these new treatments. Governments in Europe are providing support for the development of drugs to treat Alzheimer's disease. This includes funding for research and development, as well as regulatory support to help get new drugs approved for use in the market. The prevalence of Alzheimer's disease in Europe is on the rise, with an increasing number of people being diagnosed with the disease each year. This is one of the key drivers of growth in the market, as it has led to an increased demand for drugs to treat the condition.

Market Restraints

Despite the fact that various medications are available to treat Alzheimer's disease, their efficacy is limited and they sometimes only provide brief relief of symptoms. This can make meeting the requirements of patients and their families difficult, as well as limiting the market growth. There are currently no disease-modifying treatments for Alzheimer's disease, which may limit the efficacy of existing medications. Disease-modifying medicines have the ability to decrease disease progression, and their absence constitutes a huge unmet market need. The regulatory standards for new Alzheimer's disease treatments are strict, making it difficult for companies to get their drugs approved. This can cause delays in the release of new treatments and increase development expenses.

Competitive Landscape

Key Players

• Eisai Co.
• Biogen
• Eli Lilly and Company
• H. Lundbeck A/S
• Johnson and Johnson
• F. Hoffmann-La Roche AG
• Novartis AG
• Pfizer

Recent Updates

The greatest contribution of the European Alzheimer's Alliance (EAA) has been building up the work of the European Dementia Ethics Network, as well as the close follow-up and monitoring of the development and implementation of national strategies to address memory-disabling diseases in various member states.

Healthcare Policies and Regulatory Landscape

Jan 2023: Mental Health Initiative

Dementia is a policy issue that affects several areas, including health, research, disability rights, and elderly people. Within healthcare systems, the illness is frequently treated by many medical disciplines, including mental health and psychiatry, neurology, and gerontology.

Dementia falls under mental health in the WHO and WHO Europe administrative frameworks, and dementia is especially addressed by the latter through the European Framework for Action on Mental Health (EFAMH) and the related Mental Health Coalition, in which Alzheimer Europe participates. There is a dedicated workstream within EFAMH focusing on the mental health of older people, which focuses on dementia and other causes of poor mental health in older people (e.g. social isolation, stigma, etc.)

Nov 2007: European Alzheimers Alliance

Members of the European Parliament (MEPs) convened in Paris and formally launched the European Alzheimers Alliance, a collaboration between Alzheimer Europe and its member organizations to make dementia a European public health priority (EAA). The international and cross-party Alliance gathered Parliamentarians to support European persons suffering from Alzheimer's disease or another form of dementia, as well as informal or family carers.

Reimbursement Scenario

The reimbursement scenario for Alzheimer's drugs in Europe can vary depending on the country and the specific drug in question. Generally, in Europe, the reimbursement of drugs is the responsibility of individual countries, which may have different policies and procedures for reimbursement.

In many European countries, Alzheimer's drugs are reimbursed under national health systems, which provide coverage for the cost of drugs to patients who meet certain eligibility criteria. These criteria may include factors such as disease severity, age, and other medical conditions.

In some countries, such as the UK, Alzheimer's drugs are provided free of charge to patients through the National Health Service (NHS), while in other countries, patients may be required to make a co-payment for the drugs.